In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites

STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath – a European multicenter clinical study evaluating performance of INIFY® Prostate in routine clinical practice – were presented at the European Congress of Pathology by […]
Read More

ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate

STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. […]
Read More

ContextVision & The Pathologist’s INIFY® webinar – now with on-demand access

On March 25, 16:00 CET (15:00 GMT), ContextVision and The Pathologist teamed up to host a free webinar: "Experience and results from using INIFY® Prostate Screening – in the fully digitalized pathology workflow at Cannizzaro Hospital, Italy". Here, Dr Filippo Fraggetta shared his experience of using INIFY Prostate Screening, as well as preliminary results from the hospital's ongoing clinical study. Now available on demand – register here for access.
Read More

ContextVision announces first digital pathology patent granted for its unique and objective data-generation method

Master Annotation method has received patent protection in the U.S. The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
Read More